{"doi":"10.1093/infdis/jiae274","title":"The Clinical Effectiveness of Fidaxomicin Compared to Vancomycin in the Treatment of <i>Clostridioides difficile</i> Infection, A Single-Center Real-World Experience","abstract":"BACKGROUND: The use of fidaxomicin is recommended as first-line therapy for all patients with Clostridioides difficile infection (CDI). However, real-world studies have shown conflicting evidence of superiority. METHODS: We conducted a retrospective single-center study of patients diagnosed with CDI between 2011 and 2021. A primary composite outcome of clinical failure, 30-day relapse, or CDI-related death was used. A multivariable cause-specific Cox proportional hazards model was used to evaluate fidaxomicin compared to vancomycin in preventing the composite outcome. A separate model was fit on a subset of patients with C. difficile ribotypes adjusting for ribotype. RESULTS: There were 598 patients included, of whom 84 received fidaxomicin. The primary outcome occurred in 8 (9.5%) in the fidaxomicin group compared to 111 (21.6%) in the vancomycin group. The adjusted multivariable model showed fidaxomicin was associated with 63% reduction in the risk of the composite outcome compared to vancomycin (hazard ratio [HR] = 0.37; 95% confidence interval [CI], .17-.80). In the 337 patients with ribotype data after adjusting for ribotype 027, the results showing superiority of fidaxomicin were maintained (HR = 0.19; 95% CI, .05-.77). CONCLUSIONS: In the treatment of CDI, we showed that real-world use of fidaxomicin is associated with lower risk of a composite end point of treatment failure.","journal":"The Journal of Infectious Diseases","year":2024,"id":448685,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8833,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":376937,"name":"Jennifer Chow","orcid":"0000-0002-4800-7979","position":1,"is_corresponding":false},{"id":731740,"name":"Angie Mae Rodday","orcid":"0000-0002-8671-3401","position":2,"is_corresponding":false},{"id":1268073,"name":"L. A. McDermott","orcid":null,"position":3,"is_corresponding":false},{"id":498168,"name":"Seth T. Walk","orcid":"0000-0001-6891-8537","position":4,"is_corresponding":false},{"id":74667,"name":"David M. Kent","orcid":"0000-0002-9205-5070","position":5,"is_corresponding":false},{"id":29672,"name":"David R. Snydman","orcid":"0000-0003-0119-3978","position":6,"is_corresponding":false},{"id":1084890,"name":"Majd Alsoubani","orcid":"0000-0003-1239-3510","position":0,"is_corresponding":true}],"reference_count":31,"raw_metadata":null,"created_at":"2026-07-19T02:02:12.215092Z","pmid":"38779889","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}